SOURCE: HTG Molecular Diagnostics
TUCSON, AZ--(Marketwire - Jul 30, 2012) - HTG Molecular Diagnostics, a privately-held company providing products for gene expression profiling, has achieved ISO 13485:2003 certification for the design, manufacture, and distribution of instruments, software, reagents and test kits used in the analysis of gene expression. The certification covers the design, development, production, and sale of the patented qNPA technology-based products and services in HTG Molecular Diagnostics' portfolio.
To earn this internationally recognized quality standard certification, an organization is required to demonstrate it has quality management systems in place to consistently meet customer and regulatory requirements for design and development of medical devices.
"The achievement of the ISO 13485:2003 certification demonstrates HTG Molecular Diagnostics' commitment to quality and attention to detail in the development and provision of qNPA technology-based products and services, laying a solid foundation for the future growth of HTG's clinical diagnostics business," stated Sam Rua, Vice President of Regulatory Affairs and Quality Systems at HTG Molecular Diagnostics.
ABOUT HTG MOLECULAR DIAGNOSTICS:
HTG Molecular Diagnostics is a privately-held, Tucson-based company providing products for gene expression profiling, miRNA and mRNA measurement for clinical research, early drug discovery companion diagnostic and prognostic applications in oncology. The company's qNPA molecular technology platform is well-suited for reliably detecting changes in gene expression levels especially from formalin-fixed, paraffin-embedded (FFPE) tissue. Additional information is available at www.htgmolecular.com.